[Coumarin therapy during antirheumatism therapy with sulindac].
Possible interactions between the new non-steroidal antirheumatic drug Sulindac and a coumarin derivative have been investigated. 20 subjects, who required anticoagulation therapy for a variety of medical conditions, were treated for 4 consecutive weeks with Sulindac at varying dosages (200-400 mg per day). Prothrombin time, Thrombotest and bleeding time were not significantly affected by the concurrent administration of Sulindac. It can be concluded that there is no clinically important interaction between phenprocoumon and the doses of sulindac that are considered effective in rheumatic disorders. There were some moderate side effects, only one drop out was registered because of gastro-intestinal bleeding (melaena).
D015110:4-Hydroxycoumarins / Q000008:administration & dosage*; D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D002318:Cardiovascular Diseases / Q000188:drug therapy; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007192:Indenes / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010644:Phenprocoumon / Q000008:administration & dosage*; D012216:Rheumatic Diseases / Q000188:drug therapy; D013467:Sulindac / Q000008:administration & dosage / Q000009:adverse effects*
D015110:4-Hydroxycoumarins; D007192:Indenes; D013467:Sulindac; D010644:Phenprocoumon
Coumarintherapie unter dem Antirheumaticum Sulindac.